NASDAQ$RNA

Atrium Therapeutics Inc · Q1 2025 earnings

Q1 2025 earnings ·

Briefing

RNA Q1 2025 — $1.6M revenue, 0.90 EPS

Any of these actions could materially harm the Company’s business, results of operations and future prospects. Atrium Therapeutics Inc reported Q1 2025 results. Diluted EPS came in at $0.90. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $1.6M.
  • Diluted EPS: $0.90.
  • Filed on Form 10-Q (accession 0001599901-25-000106).

Headline financials

Total Revenue

$1.57M

Previous: $3.54M-55.6%
EPS (adj)

$0.90

Previous: -$0.79+213.9%
Capital Expenditures

-$3.75M

Previous: -$915K-310.2%
Free Cash Flow

-$120M

Previous: -$69.8M-71.3%
Net Income

-$116M

Previous: -$68.9M-68.1%
Operating Income

-$132M

Previous: -$77.2M-70.4%

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$1.57M

Q1 2025-55.6%vs Q1 2024
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro